Royal Veterinary College Research Identifies Early Indicator of Anaemia Treatment Side Effects in Dogs
Being able to identify dogs at risk of side effects sooner could be particularly valuable for those on longer-term glucocorticoid treatment, where side effects can have a significant impact on quality of life.

New research from the Royal Veterinary College (RVC) has found that changes in a routinely measured blood enzyme may give veterinarians an early indication of which dogs are at risk of side effects from treatment for immune-mediated haemolytic anaemia (IMHA). The findings could help vets identify these dogs sooner and adjust their care to reduce the impact on quality of life.
IMHA is a serious condition in which a dog’s immune system mistakenly identifies its own red blood cells as a threat and destroys them. It can cause severe weakness, pale or yellow gums and fast breathing, and is associated with mortality rates of up to 35 to 70%. It is also the most common immune-mediated disease in dogs. While any breed can be affected, Cocker Spaniels, Springer Spaniels, Irish Setters and Maltese Terriers are reported to be at higher risk.
Treatment aims to suppress the immune response and restore healthy red blood cell levels, but the medications used, including glucocorticoids (a type of steroid), can cause significant side effects such as increased thirst and urination, especially with longer-term use. In some cases, these effects may contribute to decisions to euthanise dogs even when the disease itself is under control. Understanding how individual dogs respond therefore helps vets strike a balance between treating the disease effectively and keeping side effects to a minimum.
Led by Dr Barbara Glanemann, Associate Professor in Small Animal Internal Medicine at the RVC, the researchers analysed data from 29 pet dogs diagnosed with IMHA at the RVC’s Queen Mother Hospital for Animals through the initial stages of their treatment. The team used blood samples already collected as part of the dogs’ routine clinical care and monitored changes in test results, clinical measures and the activity of genes linked to the immune system and steroid treatment.
The study, which has been published in the scientific journal PLoS One, found that early rises in alkaline phosphatase (ALP) activity, a liver enzyme, were associated with excessive drinking two to three weeks later. The researchers also found that many laboratory and clinical measurements changed substantially as treatment progressed, providing the first detailed picture of how these measures shift during the early treatment of IMHA.
Being able to identify dogs at risk of side effects sooner could be particularly valuable for those on longer-term glucocorticoid treatment, where side effects can have a significant impact on quality of life. Further work is now needed to establish how these changes could be used to guide treatment decisions for individual dogs.
Dr Barbara Glanemann, Associate Professor in Small Animal Internal Medicine at the RVC, said: “Our findings suggest commonly available laboratory changes early in treatment may help us all to better understand how an individual patient is responding and how high their risk is for developing adverse effects. This can help us to individualise our treatment strategies.”
This research was funded by grants from the Kennel Club Charitable Trust and the Animal Care Trust, which is the RVC’s registered charity. Point-of-care direct antiglobulin tests were kindly provided at reduced cost by Alvedia Ltd.




